Market Place
Sourcing Support
ImmuneOncia Reveals Phase 1b Results for CD47 Antibody at ASCO
02 Jun 2025 //
PR NEWSWIRE
ImmuneOncia`s CD47 Antibody Phase 1 Biomarker Results At ASCO
03 Jun 2024 //
BUSINESSWIRE
ImmuneOncia Announces Phase 1 Results of CD47 Antibody at ESMO 2023
23 Oct 2023 //
BUSINESSWIRE
ImmuneOncia Announces PII Results of PD-L1 Immune Checkpoint Inhibitor at ESMO
05 Dec 2022 //
BUSINESSWIRE
Korean startup ImmuneOncia enhances biologics portfolio for cancer patients
29 Dec 2021 //
BIOSPECTRUMASIA
ImmuneOncia, WuXi Biologics partner for bispecific antibody development
29 Dec 2021 //
PHARMACEUTICAL-TECHNOLOGY
ImmuneOncia and 3D Medicines Signed Exclusive License Agreement
30 Mar 2021 //
PRNEWSWIRE
Samsung Biologics and ImmuneOncia sign multi-product development
15 Jul 2020 //
PRNASIA
Samsung Biologics & ImmuneOncia sign multi-product Dev & MFG agreement
15 Jul 2020 //
PRNEWSWIRE
Samsung Biologics, ImmuneOncia enter manufacturing development agreement
14 Jul 2020 //
BIOSPECTRUMASIA
Samsung Biologics & ImmuneOncia Development and Manufacturing Agreement
24 Apr 2020 //
YAHOO
Samsung Biologics & ImmuneOncia Development, Mfg Agreement IND IMC-002
22 Apr 2020 //
PR NEWSWIRE
Immune-Onc Therapeutics Prepares for its Next Phase of Growth
18 Nov 2019 //
BUSINESS WIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.